Connect your AI

Relay Therapeutics, Inc. RLAY Price / book

Price / book at other companies

CelcuityCELC

103.1×+98.7×

Revolution Medicines, Inc.RVMD

12.8×+9.7×

Ligand PharmaceuticalsLGND

4×+1.4×

Cogent Biosciences, Inc.COGT

10.3×+7.2×

Tango TherapeuticsTNGX

7.6×+6.7×

Spyre Therapeutics, Inc.SYRE

5.9×+3.9×

Other financials

Income statement

Revenue$3.0M-60.9%

Operating income-$78.6M+7.4%

Net income-$73.3M+4.9%

EPS (diluted)-$0.41+10.9%

Balance sheet

Cash & equivalents$204.6M+119%

Total debt$31.6M-33.1%

Total equity$642.2M-10.9%

Total assets$699.6M-12.5%

Cash flow

Operating cash flow-$51.1M+30.2%

CapEx$1.0K—

Free cash flow-$44.9M+22.5%

Valuation

Market cap$3.46B+300%

Enterprise value$3.29B+304%

P/S324.1×+212×

Profitability

Operating margin-2,776.6%-820pp

Net margin-2,554.1%-745pp

FCF margin-1,536%-429pp

Returns & leverage

Return on equity-40%-4.3pp

Debt / equity0×0.0×

Current ratio22.1×+2.2×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=2.8×

Based on the most recent quarter.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Relay Therapeutics, Inc.'s price / book?: Relay Therapeutics, Inc. (RLAY) reported price / book of 2.8× in Q1 2026.
How has Relay Therapeutics, Inc.'s price / book changed year-over-year?: Relay Therapeutics, Inc.'s price / book increased by 349.6% year-over-year, from 0.6× to 2.8×.
What is the long-term trend for Relay Therapeutics, Inc.'s price / book?: Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s price / book has grown at a -12.0% compound annual growth rate (CAGR), from 4.9× to 2.6×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.